Cencora, Inc. (COR)
Healthcare · NYQ · US
Price as at 30 Sept 2026, 17:13 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Cencora, Inc. trades at $305.05, which is 16% below the $354.93 our fair value estimate puts on the business. On that measure alone it screens as undervalued, though a valuation model is an argument rather than a measurement, and the market is frequently right about why something is cheap.
Our moat model scores it 36 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
It changes hands at 22.8 times earnings. Be careful reading that in isolation: for a cyclical business a low P/E arrives at the top of the cycle, when profits are peaking and about to fall, which is exactly when the shares look cheapest and are not.
COR dividend history
Dividends per share by year
| Year | Total per share | Payments |
|---|---|---|
| 2026 (year to date) | $1.80 | 3 |
| 2025 | $2.25 | 4 |
| 2024 | $2.08 | 4 |
| 2023 | $1.97 | 4 |
| 2022 | $1.87 | 4 |
| 2021 | $6.82 | 8 |
| 2020 | $6.59 | 8 |
| 2019 | $6.36 | 8 |
| 2018 | $1.54 | 4 |
| 2017 | $1.48 | 4 |
| 2016 | $1.39 | 4 |
Split-adjusted amounts in the listing currency, grouped by the calendar year of the ex-dividend date, from the filed record. Growth and streak figures compare complete years only.
COR earnings and analyst estimates
Recommendation mix, 14 published ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About Cencora, Inc.
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
COR passes 2 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
17 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Capital Research Global, Capital Research Global Investors$560.28M · 0.1% of book
- Ken Griffin, CITADEL ADVISORS LLC$386.73M · 0.0% of book
- Arrowstreet Capital, ARROWSTREET CAPITAL, LIMITED PARTNERSHIP$294.33M · 0.1% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$268.97M · 0.1% of book
- Burgundy Asset Management, Burgundy Asset Management Ltd.$174.89M · 1.6% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Politician trades in COR
We hold 11 disclosed trades in COR by members of Congress and executive-branch officials. The latest 5:
- Donald J Trump · Executive branchBuy · $50,001 - $100,000 · traded 12 Jun 2026 · disclosed 22 Aug 2026
- Donald J Trump · Executive branchSell · $100,001 - $250,000 · traded 18 May 2026 · disclosed 1 Jul 2026
- Donald J Trump · Executive branchSell · $50,001 - $100,000 · traded 11 May 2026 · disclosed 1 Jul 2026
- Jared Moskowitz · HouseSell · $1,001 - $15,000 · traded 6 May 2026 · disclosed 19 Jun 2026
- Jared Moskowitz · HouseSell · $1,001 - $15,000 · traded 6 May 2026 · disclosed 19 Jun 2026
A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.
COR peers
The largest companies in the same industry (Medical Distribution), then in the same sector.
- EBO.AX EBOS Group Limited
- AHG Akso Health Group
- EMPG Empro Group Inc.
- NOVO-B.CO Novo Nordisk
- LLY Eli Lilly and Company
- JNJ Johnson & Johnson
- ABBV AbbVie Inc.
- MRK Merck & Co., Inc.
Every healthcare company we cover is on the Healthcare hub.
Common questions
Is Cencora, Inc. (COR) undervalued?
Against our fair value estimate of $354.93, COR at $305.05 is 16% below fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.
Which funds own COR?
17 of the institutions we track reported a position in COR in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
What is COR's P/E ratio?
COR trades at 22.8 times earnings. A low P/E is not automatically cheap: on a cyclical company it is usually a warning that earnings are at a peak.
Does Cencora, Inc. (COR) pay a dividend?
Yes. Cencora, Inc. yields 0.78% at the current share price. It has paid $2.40 per share over the trailing twelve months. It has paid a dividend in each of the last 25 complete calendar years. A dividend is declared by the board and can be cut at any time; a yield is a fact about the current price, not a promise.
When does COR report earnings next?
Cencora, Inc. is scheduled to report on 4 Nov 2026. Companies move earnings dates, so read it as scheduled rather than certain.
Where does SteadyShares get its COR data?
Fundamentals for COR come from company filings and exchange data, as listed on NYQ; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 17:13 UTC and is delayed. Our data quality score for this company is 100/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for COR, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.